800-Patient study aims to uncover best treatments for kidney disease

NCT ID NCT06926244

Recruiting now Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This observational study will follow 800 adults with IgA nephropathy, a common kidney disease, to see how well current treatments control protein in the urine and preserve kidney function over 12 months. Researchers want to understand why some patients do not respond to standard therapies. The study does not test a new drug but gathers real-world data to guide future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could identify which treatments work best in real-world settings for IgA nephropathy, helping doctors choose more effective therapies.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by differences in patient care and adherence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IGA NEPHROPATHY (IGAN)

Contacts and locations

Locations

Nephrology department, Hospital Pitié - Salpêtrière (ASSISTANCE PUBLIQUE HOPITAUX DE PARIS AP-HP)
RECRUITING

Paris, 75013, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.